Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 12, Alnylam Pharmaceuticals reported its earnings for 2025, with nearly $3 billion in total revenue, which was an 81% increase year-over-year. Q4 was particularly strong, with net product revenue reaching $995 million, fueled by a 151% year-over-year surge in the TTR franchise following the successful launch of Amphotra for ATTR cardiomyopathy.

In this quarter, Alnylam also launched Cyreli, which is a new RNAi manufacturing platform designed to expand capacity and reduce long-term costs. Looking ahead to 2026, the company issued optimistic guidance, forecasting combined net product sales between $4.9 billion and $5.3 billion, despite anticipating a modest mid-single-digit decrease in net pricing for its core products.

Leadership emphasized the strength of Alnylam Pharmaceuticals Inc.’s (NASDAQ:ALNY) internal pipeline, which includes over 25 active clinical programs. Executives also highlighted the potency of the company’s ACVR1C asset in the obesity space and the long-term potential for products like Nrierran to drive operating margins into the mid-40s by 2030.

Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the US, Europe, and internationally.

While we acknowledge the potential of ALNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALNY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.